YTHDF1 enhances stemness and chemoresistance in triple‐negative breast cancer cells by upregulating SIAH2
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer, and chemoresistance is the major determinant of TNBC treatment failure. This study explores the molecular mechanism of TNBC chemoresistance. The Cancer Genome Atlas, breast cancer integrative platform, and GEPIA databases were used to analyze the expression and correlation of YTHDF1 and seven in absentia homology 2 (SIAH2) in breast cancer. Knockdown of YTHDF1 and SIAH2, or overexpression of SIAH2 in vitro and in vivo, was conducted to evaluate the impact of changes in YTHDF1 and SIAH2 expression on TNBC cell proliferation, apoptosis, stemness, drug resistance, and Hippo pathway gene expression. YTHDF1 and SIAH2 were highly expressed in breast cancer patients and TNBC cells. Knockdown of YTHDF1 and SIAH2 significantly inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. Mechanistically, the knockdown of YTHDF1 inhibited the expression of SIAH2, thereby downregulating the Hippo pathway, which inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. The current findings revealed the regulatory mechanism of YTHDF1 in TNBC and clarified the role of the YTHDF1/SIAH2 axis in TNBC drug resistance and stemness. This could provide new insights into the vital role of targeting YTHDF1/SIAH2 to suppress drug resistance and stemness in TNBC cells.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- YTHDF1 enhances stemness and chemoresistance in triple‐negative breast cancer cells by upregulating SIAH2
- Date Crossref
- 20/11/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kunming Medical University Department of Mammary Surgery I pays non établi dans la noticeUniversité ou école supérieure
-
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture Department of Tumor 2 Families pays non établi dans la noticeÉtablissement de santé
-
Kunming University of Science and Technology Department of Blood Transfusion pays non établi dans la noticeUniversité ou école supérieure
-
First People's Hospital of Yunnan Province pays non établi dans la noticeÉtablissement de santé
-
Yunnan Maternal and Child Health pays non établi dans la noticeÉtablissement de santé
-
Department of Tumor 2 Families Central Hospital of Enshi Tujia and Miao Autonomous Prefecture Enshi China pays non établi dans la noticeÉtablissement de santé
-
Department of Kunming Maternal and Child Health Service Centre Kunming City Maternal and Child Health Hospital Kunming China Department of Kunming Maternal and Child Health Service Centre pays non établi dans la noticeÉtablissement de santé
Department of Mammary Surgery I — Kunming Medical University, Department of Tumor 2 Families — The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture et Department of Blood Transfusion — Kunming University of Science and Technology, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.